Publications by authors named "Barbara McGovern"

Claim this Profile
C
Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection.
Jessica A Bryant, Timothy J Straub, Darrell S Pardi, Kevin D Litcofsky, Colleen R Kelly, Barbara H McGovern

J Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Colleen S Kraft, Matthew Sims, Michael Silverman, Thomas J Louie, Paul Feuerstadt, Barbara H McGovern

Infect Dis Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Colleen S Kraft, Matthew Sims, Michael Silverman, Thomas J Louie, Paul Feuerstadt, Barbara H McGovern

Infect Dis Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
End-to-end donor screening and manufacturing controls: complementary quality-based strategies to minimize patient risk for donor-derived microbiome therapeutics.
Jason Goldsmith, Sarah Tomkovich, John G Auniņš, Barbara H McGovern, Jennifer C Mahoney

Gut Microbes· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.
Timothy J Straub, Mary-Jane Lombardo, Jessica A Bryant, Liyang Diao, Thomas P Lodise, Barbara H McGovern

Clin Infect Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
Charles S Berenson, Bret Lashner, Louis Y Korman, Elizabeth Hohmann, Abhishek Deshpande, Barbara H McGovern

Clin Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool.
Christopher W J McChalicher, Mary-Jane Lombardo, Sahil Khanna, Gregory J McKenzie, Elizabeth M Halvorsen, Barbara H McGovern

J Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection-Reply.
Stuart H Cohen, Thomas J Louie, Barbara H McGovern

JAMA· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
Matthew D Sims, Sahil Khanna, Paul Feuerstadt, Thomas J Louie, Colleen R Kelly, Barbara H McGovern

JAMA Netw Open· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial.
Kevin W Garey, Jinhee Jo, Anne J Gonzales-Luna, Brittany Lapin, Abhishek Deshpande, Barbara McGovern

JAMA Netw Open· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.
Stuart H Cohen, Thomas J Louie, Matthew Sims, Elaine E L Wang, Asli Memisoglu, Barbara H McGovern

JAMA· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool.
Christopher McChalicher, Ahmad Abdulaziz, S Steve Zhou, Mary-Jane Lombardo, Brooke Hasson, Barbara H McGovern

Open Forum Infect Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SER-109 for Recurrent Clostridioides difficile Infection. Reply.
Paul Feuerstadt, Barbara H McGovern

N Engl J Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SER-109, an Oral Microbiome Therapy for Recurrent Infection.
Paul Feuerstadt, Thomas J Louie, Bret Lashner, Elaine E L Wang, Liyang Diao, Barbara H McGovern

N Engl J Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quilting emergent advanced practice nursing educator identity: an arts-informed approach.
Emma MacGregor, Nicole Serre, Teresa Cozzella, Barbara McGovern, Lori Schindel Martin

Int J Nurs Educ Scholarsh· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
Barbara H McGovern, Christopher B Ford, Matthew R Henn, Darrell S Pardi, Sahil Khanna

Clin Infect Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
Matthew R Henn, Edward J O'Brien, Liyang Diao, Brian G Feagan, William J Sandborn, Barbara H McGovern

Gastroenterology· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Infection: Current Understanding and Gap Analysis.
Mark H Wilcox, Barbara H McGovern, Gail A Hecht

Open Forum Infect Dis· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.
Sahil Khanna, Darrell S Pardi, Colleen R Kelly, Colleen S Kraft, Tanvi Dhere, Barbara H McGovern

J Infect Dis· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.
Behzad Hajarizadeh, Bart Grady, Kimberly Page, Arthur Y Kim, Barbara H McGovern

PLoS One· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy.
Prajakta S Badri, Jennifer R King, Akshanth R Polepally, Barbara H McGovern, Sandeep Dutta

Clin Pharmacokinet· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative.
Kimberly Page, Ali Mirzazadeh, Thomas M Rice, Jason Grebely, Arthur Y Kim, Barbara H McGovern

Open Forum Infect Dis· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.
Rachel Sacks-Davis, Jason Grebely, Gregory J Dore, William Osburn, Andrea L Cox, Barbara H McGovern

J Infect Dis· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Jacob Lalezari, J Greg Sullivan, Peter Varunok, Edward Galen, Kris V Kowdley, Barbara McGovern

J Hepatol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review.
Shauna Onofrey, Jasneet Aneja, Gillian A Haney, Ellen H Nagami, Alfred DeMaria, Barbara H McGovern

Ann Intern Med· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis